These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10671757)

  • 1. Flucytosine: correlation between toxicity and pharmacokinetic parameters.
    Vermes A; van Der Sijs H; Guchelaar HJ
    Chemotherapy; 2000; 46(2):86-94. PubMed ID: 10671757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of flucytosine-induced thrombocytopenia using creatinine clearance.
    Vermes A; Guchelaar HJ; Dankert J
    Chemotherapy; 2000; 46(5):335-41. PubMed ID: 10965099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.
    Vermes A; Guchelaar HJ; van Kuilenburg AB; Dankert J
    Fundam Clin Pharmacol; 2002 Feb; 16(1):39-47. PubMed ID: 11903511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.
    Vermes A; Guchelaar HJ; Dankert J
    J Antimicrob Chemother; 2000 Aug; 46(2):171-9. PubMed ID: 10933638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [5-Fluorocytosine. A neglected systemic antimycotic in Czechoslovakia].
    Otcenásek M; Kejda J
    Cas Lek Cesk; 1989 Oct; 128(43-44):1385-9. PubMed ID: 2598255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of treatment involving 5-fluorocytosine].
    Dellamonica P; Fournier JP; Garraffo R; Lapalus P; Bernard E; Chichmanian RM; Marty P; Le Fichoux Y
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):642-5. PubMed ID: 3911161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [5-Fluorocytosine and combinations].
    Polak A
    Ann Biol Clin (Paris); 1987; 45(6):669-72. PubMed ID: 3326438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow toxicity associated with 5-fluorocytosine therapy.
    Kauffman CA; Frame PT
    Antimicrob Agents Chemother; 1977 Feb; 11(2):244-7. PubMed ID: 848928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [5-fluorocytosine--a new drug for treatment of severe mycotic infections].
    Alestig K; Eilard T; Norrby R
    Lakartidningen; 1975 Oct; 72(41):3929-30. PubMed ID: 1100947
    [No Abstract]   [Full Text] [Related]  

  • 10. Experimental intravitreal 5-fluorocytosine.
    Yoshizumi MO; Silverman C
    Ann Ophthalmol; 1985 Jan; 17(1):58-61. PubMed ID: 3977219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of fungal infections with flucytosine.
    Harder EJ; Hermans PE
    Arch Intern Med; 1975 Feb; 135(2):231-7. PubMed ID: 1096840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.
    Béguin J; Kohlhauer M; Laloy E; Degorce F; Moreau B; Quéméneur É; Erbs P; Klonjkowski B; Maurey C
    BMC Vet Res; 2021 Jun; 17(1):220. PubMed ID: 34154593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida pyarthrosis. Report of a case and results of treatment with 5-fluorocytosine.
    Umber J; Chapman MW; Drutz DJ
    J Bone Joint Surg Am; 1974 Oct; 56(7):1520-4. PubMed ID: 4433374
    [No Abstract]   [Full Text] [Related]  

  • 14. [Results of 5-fluorocytosine therapy of aspergillosis and candidiasis].
    Rudnicka J; Halweg H; Krakówka P; Walczak J
    Pneumonol Pol; 1981 Mar; 49(3):209-17. PubMed ID: 7027197
    [No Abstract]   [Full Text] [Related]  

  • 15. Agranulocytosis associated with flucytosine for urinary candidiasis.
    Wise GJ; Goldberg P; Kozinn PJ; Nawabi IU
    Urology; 1976 Nov; 8(5):490-1. PubMed ID: 982739
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of Candida peritonitis by prolonged peritoneal lavage containing 5-fluorocytosine.
    Holdsworth SR; Atkins RC; Scott DF; Jackson R
    Clin Nephrol; 1975 Oct; 4(4):157-9. PubMed ID: 1192617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of sepsis by Candida in renal patients with 5-fluorocytosine].
    Rodicio JL; Ortuño MT; Alés JM; Hernando L
    Rev Clin Esp; 1974 Sep; 134(6):575-8. PubMed ID: 4615347
    [No Abstract]   [Full Text] [Related]  

  • 18. Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis.
    Roberts JA; Udy AA; O'Donoghue S; Briscoe S; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2009 Oct; 34(4):383-4. PubMed ID: 19540094
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
    Hope WW; Warn PA; Sharp A; Reed P; Keevil B; Louie A; Walsh TJ; Denning DW; Drusano GL
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3760-2. PubMed ID: 17682101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis.
    van der Voort PH; Boerma EC; Yska JP
    J Antimicrob Chemother; 2007 May; 59(5):952-6. PubMed ID: 17389717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.